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This study was set out to find out the pattern of antimalarial drug use in a Nigerian rural community following the aggressive 
price subsidy of Artemisinin Combination Therapy(ACT) recently embarked upon by Roll Back Malaria partners through 
Affordable Medicines Facility-malaria (AMFm). 
Methods 
Questioners were administered to 310 adult members of the community with the most recent malaria episodes so as to find out 
about the drugs used and some of the factors associated with the choice of the drug. 
Result 
Although the overall use of ACT (13.55%) in this community was about 4 times higher than what it used to be, Chloroquine 
123(39.62%) and sulphadozine/pyrimathamine 120(38.71%) were the mostly used antimalarial agents. Choice of drug used was 
significantly associated with perception of efficacy and price among other factors. Respondents liked the price of ACT (33.3%) 
most, CQ was the drug most liked in terms of efficacy (44.2%) while SP was the drug most liked in terms of lack of side effect 
(38.9%), taste (61.6%) and convenience (35.7%).( P= 0.001) 
Conclusion 
 
In addition to sustaining the current price control, there is a need to continuously monitor and effectively regulate the quality of 
the ACTs in circulation so as to gain the confidence of both the prescribers and the end users regarding efficacy and adherence 
to ACTs. This will help to safeguard the huge investment in ACT subsidy by the Roll Back Malaria partners. 
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INTRODUCTION 
The 2008 World Malaria Report showed that only 3% 
of children with suspected malaria were treated with 
Artemisinin Combination Therapy (ACT), suggesting 
that many children were still  receiving chloroquine 
and  sulphadoxine/pyrimethamine for  malaria 
treatment despite the recommended change in 
treatment guidelines [1]. A published study that 
evaluated 21 African countries for their antimalarial 
use  in  2006-2007 showed  that  only  three  countries 
reported   high   use   of   the   regimen   that   was   in 
agreement with the national treatment guideline [2]. 
The study further revealed that chloroquine was the 
most common anti-malarial reported in 14 of 21 
countries , and reported use was particularly high in 
West Africa. 
 
A descriptive study that evaluated the anti-malarial 
drug prescribing practice in private and public health 
88 
facilities in South-East Nigeria also showed that only 
3.0%   of   patients   were   treated   with   artemisinin 
combination   therapy.   Most   of   the   patientswere 
treated with chloroquine (30.2%), sulphadoxine/ 
pyrimethamine (22.7%) orartemisininmonotherapy 
(15.8%)  despite  the  change  in  the  national malaria 
treatmentpolicy [3]. 
 
Treatment of malaria in pregnancy was not exempted 
from  the  protocolviolation. A  recent  survey  of  the 
patterns of anti-malarial drug treatment among 
pregnantwomen in Uganda showed that only 5.6% of 
the   pregnant  women  in   their  first  semesterwere 
treated according to the national guideline while 70% 
were treated withcontraindicated anti-malarial drugs. 
Recommended   antimalarial   were   used   according 
tothe guidelines in only 30.1% of all second and third 
trimester episodes [4].Some of  the factors that that 
have  been  found  to  positively influence the  use  of 
clinical 
guidelines   include   clarity   of    guidelines,   strong 
evidence, adequate funding of guidelines and support 
by   opinion  leaders  especially  professional  bodies 
[5].The reluctance to abandon chloroquine is based, in 
part,  on  its  low  cost, wide availability, and 
acceptance. Chloroquine results in rapid initial 
improvement of clinical symptoms, which has 
contributed to its widespread acceptance and the 
perception that it remains effective, leading to an 
unwillingness of both health workers and patients to 
discontinue using chloroquine despite its reduced 
efficacy [6].In 2004, Nigeria changed from the use of 
chloroquine   and   sulphadoxine/pyrimethamine  as 
first line anti-malarial drugs in line with the 
recommendation of the World Health Organization as 
a result of unacceptably high level of resistance to the 
formal  drugs  [7].Adherence of  patients  as  well  as 
health care providers to  the new guidelines remain 
poor in many parts of Nigeria [8-10]. 
 
Research data from Kenya provided strong evidence 
that continued use of chloroquine in areas with 
resistance was contributing to excess Plasmodium 
falciparum related  deaths [6].Apart from  vector  and 
parasite biology, pharmacokinetics, and economics 
reasons;human behavior  is  another  factor  that  has 
been associated with antimalarial drugresistance 
[11].In addition to low usage of ACTs imposed by its 
high  cost,  quality of  ACTs  in  circulationis another 
major challenge. Recent survey by the World Health 
Organization (WHO) inconjunction     with  Nigerian 
drug regulation agency showed that Nigeria has the 
highestrate of  sub-standard antimalarials (63.9%)  in 
Sub-Sahara  Africa  [1].  The  survey  furtherrevealed 
that a common problem for ACTs was that of lower 
content of  active pharmaceutical ingredients (APIs). 
This  was  further supported by  the  findings of  the 
Global Funds which showed that availability of 
quality-assured ACTs in Nigeria is only 28% [1]. 
 
The  first  attempt  to  improve  the  use  of  ACT  in 
Nigeria was in 2008 when the government took a step 
forward in subsidizing child doses of Amodiaquine- 
artesunate combination (ASAQ) via the private sector 
in 18 of the 37 states. Retailers in these 18 states could 
purchase subsidized ACTs for 5 naira ($0.03 USD) per 
treatment with an approved retail price set at 30 naira 
($0.20 USD). This was followed by widespread 
stockouts of ACTs across Nigeria as a result of 
inadequate supply. This resulted in reduced 
availability of ACTs in the public sector and increased 
prices in the private sector. End users were eventually 
forced  to  revert  back  to  the  cheaper  monotherapy 
[13]. 
Efforts to remove the obstacle imposed by high cost 
and stockouts of ACTs received another boost when 
Nigeria initiated Affordable Medicines Facility- 
malaria (AMFm) activities on October 5, 2010. AMFm 
was set by the Roll Back Malaria Partnership (RBM) 
in  2007 and managed by the Global Fund to  Fight 
AIDS, Tuberculosis and Malaria (the Global Fund). 
 
The AMFm aims to increase use of ACTs by 
subsidizing prices of ACTs at the “factory gate”. The 
subsidy will in turn be passed along the supply chain 
to the consumer, lowering ACT prices so that they are 
comparable to chloroquine, sulfadoxine- 
pyrimethamine or artemisininmonotherapy. Reduced 
prices should, in theory, “crowd out” sales of these 
other drugs and thus increase ACT use [13]. 
The aim of this study is to find out the current malaria 
treatment  practices  following  the  introduction  of 
AMFm and  some of  the factors that are associated 




This study was carried out between March and April 
2012  at  Oke-iho,  a  rural  community in  Oyo  State, 
South-West Nigeria with a population of about 12,964 
inhabitants. It is situated at 8.03° North latitude, 3.35° 
East longitude and 314 meters elevation above the sea 
level, the climate is  tropical rainforest with malaria 
transmission occurring most of the year [13-14]. 
Information about the number of streets and houses 
in this community was obtained from the local 
government authority. Eleven houses were randomly 
selected from each street by simple random sampling 
method, and then an adult with the most recent 
episode  of  malaria  was  chosen  as  participant  per 
house after informed consent was obtained. Pretested 
questionaires were administered by trained research 
assistants to participants after translation of the 
contents to their local dialects. 
 
Statistical analysis 
Data was analyzed with the free GNU PSPP Statistical 
Analysis Software version 0.7.9-gd4ae90. Using the 
descriptive statistics in the analysis command, 
frequency tables were generated for the general 
characteristics of  the  participants and  expressed in 
percentages. Association between  the  drug  used  to 
treat the last malaria episode and other variables was 




Majority (58.71%) were  females  while  201  (64.84%) 
were married (table 1).Malaria was the 4th   common 
health  problem  49  (15.16%)  experienced  by 
participants and it was experienced once to twice a 
 
89 
Secondary school certificate 163 (52.58) 
Diploma 69 (22.26) 
Unemployed 0 (3.23) 
Students 68 (21.94) 
Trading 81 (26.13) 
Farming 20 (6.45) 
Artisan 61 (19.68) 
Teaching 37 (11.94) 
Apprentice 7 (2.26) 
Headache 86 (27.74) 
Diarrhea 11 (3.55) 
Loss of appetite 50 (16.13) 
Body weakness 36 (11.61) 
Others 1 (0.32) 
year in most cases (41.61%) presenting as fever 126 




TABLE 1: SOCIODEMOGRAPIC PARAMETER OF THE 
RESPONDENTS 
 
Character                                          frequency   % 
Age 
18-20                                                 50                    (16.13) 
21-30                                                 114                  (36.77) 
31-40                                                 87                    (28.06) 
41-50                                                 31                    (10.02) 
>50                                                    28                    (9.03) 
 
Sex 
Male                                                 128                  (41.24) 
Female                                             182                  (58.71) 
 
Marital status 
Married                                            201                  (64.84) 
Single                                               09                    (35.16) 
Separated                                       0                     (0) 
 
Level of education 
No formal education (Nil)          27                    (8.71) 
Primary school certificate           40                    (12.90) 
 
Degree                                             11                    (3.55) 
Occupation 
the level of  education, ACT use increased with the 
level of education, with the highest among those with 
university degree (27.2%) while the use of  CQ was 
highest among those with no formal education 14 
(15.8%), P= 0.33, (Table 4). 
 
 
TABLE 2:. MALARIA FEATURES AMONG 
PARTICIPANTS 
 
Features                                       Frequency       % 
What is your commonest 
health problem? 
Headache                                   95                     (30.65) 
Back pain                                    50                   (16.13) 
General body aches                 94                    (30.32) 
Malaria                                        49                    (15.16) 
Menstrual pain                         3                      (0.79) 
Abdominal pain                         2                     (0.65) 
Others                                         19                    (6.13) 
 
How often do you 
experience malaria attack? 
< once per year                           39                    (12.58) 
1-2 times per year                      29                    (41.61) 
3-4 times per year                      91                     (29.35) 
4-6 times per year                      49                    (15.81) 
>6 times per year              2                     (0.65) 
 
What major sign suggest 
that you have malaria? 








Civil servants                                  10                   (3.23) 
Others                                               16                   (5.16) 
 
Tribe 
Yoruba                                               284                 (91.61) 
Ibo                                                        7                    (2.26) 
Hausa                                                 14                   (4.52) 
Fulani                                                 4                     (1.27) 
Ghanaian                                          1                     (0.32) 
 
 
Sulphadozine/pyrimathamine 92(29.68%) was mostly 
regarded as the currently recommended drug for 
treating malaria followed by chloroquine 85(27.42%). 
The drug used to treat the last episode of malaria by 
respondents included chloroquine 123(39.62%), 
sulphadozine/pyrimathamine    120(38.71%),     ACT 
82(13.55%)  and  Artesunatemonotherapy 8  (2.58%) 
(Table 3).CQ was mostly used by males (42.2%) while 
SP was mostly used by females (39.0%). 
 
Use  of  ACT  observed among females (15.9%) was 
about 1.6 times higher than in the males (10.2%), p= 
0.56. While the use of SP has no definite pattern with 
 
Friends 7(50.0%) and Chemists 15 (33.3%) were more 
likely to prescribe CQ than any other drug. Doctors 26 
(19.3%)   were   the   most   likely   to   prescribe  ACT 
followed  by  nurses  (15.4%).  P=  0.001.  ACT  was 
mostly liked for its good price (33.3%), CQ was the 
drug mostly liked in terms of efficacy (38.1%) while 
SP was the drug mostly liked in terms of lack of side 
effect (38.9%), taste (61.6%) and convenience (35.7%). 
P= 0.001. 
The  use  of  CQ  76(89.4%)  and  SP  70(76.1%)  were 
highest among those who believed that they were the 
recommended drugs for malaria while ACT 10(55.5%) 
use was also highest among those who were of the 
opinion that it was the current antimalarial of choice. 




The overall use of  ACT(13.55%) in  this community 
was about 4 times higher than recorded in 2008 [1]. 




price and probably improved availability following 
implementation of AMFm . 
 
The higher rate of ACT use and the lower rate of CQ 
use among females compared to males in this study 
may be due to the fact that females are more likely to 
receive health education regarding malaria control as 
a result of antenatal care visit [15-16]. 
 
TABLE 3: KNOWLEDGE AND ATTITUDE TOWARD 
MALARIA TREATMENT. 
 
Knowledge/Attitude                                 frequency         % 
What is the currently recommended drugin malaria 
treatment policy? 
Chloroquine                                                   85               (27.42) 
S/P-Fansidar, Amalare.t.c                         92             (29.68) 
ACT e.gCoartem                                        18              (5.81) 
Artesunate alone                                         18             (5.81) 
Ampicilin                                                    32              (10.32) 
Cotrimoxazole                                            28             (9.03) 
Others                                                          37               (11.94) 
 
Drug used during the last 
episode of malaria? 
Chloroquine                                                 123           (39.62) 
S/P-Fansidar, Amalare.t.c                         120          (38.71) 
ACT e.gCoartem                                       42             (13.55) 
Artesunate alone                                        8                (2.58) 
Ampicilin                                                    7                (2.26) 
Cotrimoxazole                                             5               (1.61) 
Others                                                         5                (1.61) 
 
Who prescribe the drug to you? 
Doctor                                                         133             (42.90) 
Nurse                                                          39               (12.62) 
Chemist                                                      73               (23.62) 
Self                                                               48              (15.53) 
Friend                                                         16              (5.16) 
 
What did you like most about 
the used drug? 
Good price                                                  15              (4.84) 
Efficacy                                                       231            (74.52) 
No side effect                                            18              (5.81) 
Taste                                                             18              (5.81) 






Though  closely  followed  by  SP  4(26.7%)  and  CQ 
3(20.0%), the fact that the price of ACT 5(33.3%) was 
what users liked most about these drugs suggested 
that  effect  of  the  recent  aggressive  subsidy 
mechanism by AMFm to lower the price ACT is being 
felt in this part of the country [13]. 
Surprisingly, participants rated the efficacy of CQ 
(44.2%) and  SP  (38.1%)  above that of  ACT  (12.6%) 
contrary to available evidence from clinical trials [17- 
18]. This may explain why these older drugs were still 
largely used in this community despite the perceived 
satisfaction with the price of ACT. 
 
This contradiction is probably because therapeutic 
efficacy trials  evaluate  clinical  and  laboratory 
evidence in children below the age of 5 years while 
this  study  sought testimonies of  adult  antimalarial 
users. It may also be due to the fact that ACTs used in 
therapeutic efficacy trials are usually of certified 
quality [19] while drugs used by patients come from 
the open market. The latter possibility is supported by 
the  recent findings of  widespread substandard and 
fake ACTs in Nigerian drug market [12-13]. 
Testimonies of  the  end  users may  also  explain the 
observed high rate of CQ and SP prescription by 
doctors and nurses in this study. 
 
Conclusion 
This  study  showed  that  though  chloroquine  and 
sulphadoxine/pyrimethamine were  still  the  major 
anti-malarial  drugs  currently  used  in  this  part  of 
Nigeria, there was an improvement in ACT use when 
compared  to  years  before  AMFm  implementation. 
Antimalarial use practices are significantly associated 
with who prescribe the drugs, 
knowledge of the current treatment guidelines as well 
of perception of efficacy by the users. Users liked the 
price of ACT but still believed in the efficacy of the 
older  drugs.  In  addition  to  sustaining  the  current 
price control, there is a need to continuously monitor 
and  effectively regulate the  quality of  the  ACTs in 
circulation so as to gain the confidence of both the 
prescribers and the end users regarding efficacy and 
adherence to ACTs. This will help to safeguard the 
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TABLE 4-: RELATIONSHIP BETWEEN SOCIODEMOGRAPHIC PARAMETERS OF THE PARTICIPANTS AND THE DRUG 
USED TO TREAT THE LAST MALARIA EPISODE. 
 
(Drug used during the last  episode of malaria) 
CQ            S/P          ACT         AM      Amp        Cotrim      Others    Total (%) 
Frequency (%) 
Age 
18-20                   22(44.0)    19(38.0)    1(2.0)      2(4.0)    2(4.0)     2(4.0)        2(4.0)     50(100) 
21-30                   42(36.8)    47(41.2)    15(13.2)  5(4.4)    4(3.5)     0(0.0)        1(0.9)     114(100) 
31-40                   29(33.3)    34(39.1)    19(21.8)  1(1.1)    1(1.1)     2(2.3)        1(1.1)     87(100) 
41-50                  14(45.2)    12(38.7)    5(16.1)    0(0.0)    0(0.0)     0(0.0)        0(0.0)     31(100) 
>50                       16(57.1)    8(28.6)      2(7.1)      0(0.0)    0(0.0)     1(3.6)        1(3.6)     28(100) 
Pearson Chi Square = 33.65, df = 36, P = 0.58 
Sex 
Male                   54(42.2)     49(38.1)     13(10.2)    5(3.9)    2(1.6)    3(2.3)     2(1.6)   128(100) 
Female                69(37.9)     71(39.0)     29(15.9)    3(1.6)    5(2.7)   2(1.1)     3(1.6)    182(100) 
Pearson Chi Square = 4.89, df = 6, P = 0.56 
Level of education 
Nil                       14(51.8)    10(37.0)      1(3.7)        0(0)        0(0)       1(3.7)       1(3.7)   27(100) 
Primary  21(52.5)12(30.0) 3(7.5)  2(5.0) 1(2.5)1(2.5)0(0) 40 (100)              Secondary          63(38.7) 
68(41.7)     19(11.7)    3(1.8)     6(3.7)     1(0.6)      3(1.8)   163 (100) 
Diploma              21(30.4)    26(37.7)       16(23.2)    3(4.3)     0(0)       2(2.9)      1(1.4)   69 (100) 
Degree                4(36.4)      4(36.4)        3(27.2)      0(0)         0(0)       0(0)          0(0)      11(100) 
Pearson Chi Square = 26.54, df = 24, P = 0.33 
CQ-choroquine,S/P –sulphadoxin/pyrimethamine,  ACT –Artemisinin combination therapy,      AM- Artesunatemonotherapy, Amp - 






































Friend 7(5.7)       3(2.5)        1(2.4)       1(12.5)      2(28.6)      1(20.0)   1(20
      16(13.0) 16(13.4) 6(14.3)    1(12.5)     0(0) 0(0) 0(0) Chemist  
32(26.0) 29(24.4) 4(9.7)      4(50.0)     1(14.3) 3(60.0) 0(0) Self  
16(13.0) 15(12.6) 7(16.7)    1(12.5)     4(57.1) 1(20.0) 4(80) Total  





TABLE 5:  RELATIONSHIP BETWEEN THE DRUGS USED TO TREAT THE LAST MALARIA EPISODE AND THE DRUG 
PRESCRIBER, WHAT THE USER LIKED MOST ABOUT THE DRUG AND THE USER’S KNOWLEDGE OF 
CURRENTLYRECOMMENDED ANTI-MALARIA DRUGS. 
 
 
(Drug used during the last  episode of malaria) 
CQ            S/P          ACT         AM           Amp        Cotrim      Others 
Frequency (%) 
 
Who prescribed theused drug 
) 





52.46 ,    df = 24,  P = 0.001 
 
What do you like mostabout the drug used? 
Cheap price                         3(2.4)         4(3.3)      5(11.9)     1(12.5)    0(0)          2(40.0)   0(0) 
Efficacy                              102(82.9)  88(73.3)    29(69.0)   3(37.5)  3 (42.9)    2(40.0)  4(80.0) 
No Side effect                     6(4.9)         7(5.8)        4(9.5)      0(0)          0(0)          1(20.0)   0(0) 
Taste                                  3(2.4)        11(9.2)        0(0)        2(25.0)    2(28.6)     0(0)        0(0) 
Convenience                      9(7.3)        10(8.3)        4(9.5)     2(25.0)   2(28.6)     0(0)        1(20.0) 
Total                                   123 (100) 120(100)    42(100)   8(100)    7(100)      5(100)     5(100) 
Pearson Chi Square     52.24,           df = 24,  P = 0.001 
 
Currently recommendeddrug in malarial treatmentpolicy, 
Chloroquine 76(61.8) 6(5.0) 3(7.1) 0(0) 0(0) 0(0) 0(0) 
S/P 7(5.7) 70(53.8) 10(23.8) 3(37.5) 0(0) 2(40.0) 0(0) 
ACT 3(2.4) 4(3.3) 10(23.8) 0(0) 1(14.3) 0(0) 0(0) 
AM 2(1.6) 3(2.5) 11(26.2) 0(0) 1(14.3) 0(0) 1(20.0) 
Ampicilin 11(8.9) 10(8.3) 2(4.8) 4(50.0) 2(28.6) 1(20.0) 2(40.0) 
Cotrimoxazole 7(5.7) 17(14.2) 0(0) 1(12.5) 2(28.6) 0(0) 1(20.0) 
Others 17(13.8) 10(8.2) 6(14.3) 0(0) 1(14.3) 2(40.0) 1(20.0) 
Total 123 (100) 120(100)    42(100) 8(100) 7(100) 5(100) 5(100) 
Pearson Chi Square 258.52,     df = 36,  P = 0.001     
 
CQ-choroquine,  S/P –sulphadoxin/pyrimethamine,  ACT –Artemisinincombination therapy, 
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